WINTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

WINDTREE THERAPEUTICS INC /DE/

Financials through Q3 FY2025, quarter ended Sep 30, 2025Last filing: 10-Q on Nov 19, 2025

$0.00+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $26.68K
P/E (TTM): –
Dividend yield: –

WINDTREE THERAPEUTICS INC /DE/ income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	–	–	–	–	–	0.20	1.79	1.49	2.04	0.99	2.84	0.39	0.20	–	–
Cost of Revenue	–	–	–	–	–	–	–	–	–	0.93	2.67	0.52	0	0	–
Gross Profit	–	–	–	–	–	–	–	–	–	0.06	0.16	-0.13	0.20	–	–
Research & Development	16	8.34	11	18	15	13	11	17	32	29	27	28	22	17	17
Selling, General & Admin	8.74	9.20	11	14	15	12	7.42	6.66	8.37	11	17	17	16	7.86	8.39
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	–	7.86	8.39
Operating Expenses	26	21	41	77	30	25	18	24	40	41	46	45	38	25	26
Operating Income	-26	-21	-41	-77	-30	-25	-16	-23	-38	-40	-43	-45	-38	-25	-26
Interest Expense	0.24	0.05	0.05	0.11	0.13	0.50	1.41	1.86	2.52	4.58	4.59	0.01	0.01	0.02	0.36
Interest & Investment Income	0.07	0.33	0.11	0.09	0.12	0.15	0.02	0.01	0.02	0.00	–	–	–	–	–
Other Non-Operating Income	24	0.31	0.76	-0.34	-2.25	-2.58	-4.34	4.10	-1.68	-16	-4.59	-1.47	-0.05	-0.01	-0.07
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	2.90	–	–	–	–	–
Asset Impairment Charges	0	3.06	13	0	0	0	0	0	0	0	0	0	0	0	–
Gain (Loss) on Investments	–	–	–	–	–	0.08	0	0	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0	-0.01	-0.02	0	–	–	0.01	–	0.02	-0.08	0	0	-0.04	-0.05	0.02
Pretax Income	-1.79	-20	-41	-78	-33	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	-0.01	0	-1.37	-9.99	0	–	–	–	–	0	0	0	0	–	–
Net Income	-1.79	-20	-39	-68	-33	-27	-21	-18	-39	-55	-44	-45	-37	-21	-19
Preferred Dividends	–	–	–	–	–	–	1.72	6.37	–	–	–	–	–	–	–
Net Income to Common	-5.49	-20	–	–	–	-27	-35	-25	-39	-56	-48	-45	-37	–	–
EPS (Basic)(per share)	-104.35	-4,718.84	-1,120.14	-2,459.52	-1,872.00	-2,259.00	-20,898.00	-65,178.00	-256,068.00	-430,920.00	-393,120.00	-619,920.00	-718,200.00	-703,080.00	-1,247,400.00
EPS (Diluted)(per share)	–	–	–	-2,457.00	-1,872.00	-2,259.00	-20,898.00	-65,178.00	-256,068.00	-430,920.00	-423,360.00	-619,920.00	-718,200.00	-703,080.00	-1,247,400.00
Shares Outstanding (Basic, Weighted)(shares)	53	4.30	0.04	0.03	0.02	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0	–
Shares Outstanding (Diluted, Weighted)(shares)	53	4.30	0.04	0.03	0.02	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	–	–	–	–	–	–	–	-22	-38	-39	-42	-44	-37	-23	-24

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Sep 30, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2024: -26.7%

Financial strength

Current ratio: 0.33
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –